جست‌وجوی استاد و پژوهشگر

Pui Leeمشاهده پروفایل

استادیار

• Autoinflammatory Diseases
• Myeloid Cell Biology
• Immunometabolism
• +۵ مورد دیگر

Dr. Pui Lee is an Attending Physician in Rheumatology at Boston Children’s Hospital and Assistant Professor of Pediatrics at Harvard Medical School. His research focuses on autoinflammatory diseases, myeloid cell biology, and immunometabolism. Education: MD-PhD, University of Florida College of Medicine (2010) Internship, Boston Children's Hospital (2011) Residency, Boston Children's Hospital (2013) Fellowship, Boston Children's Hospital (2016) Dr. Lee's primary research investigates how immunometabolism regulates monocyte development and inflammation, with emphasis on macrophage activation syndrome (MAS) and deficiency of adenosine deaminase 2 (DADA2). His laboratory explores metabolic reprogramming in myeloid cells and immune activation mechanisms in cytokine storm syndromes. Current projects include studying monocyte differentiation pathways and vascular inflammation in DADA2. His 15 most recent publications (2023-2025) demonstrate expertise in pediatric rheumatology, with recurring themes in cytokine storm pathogenesis, monocyte/macrophage biology, and genetic autoinflammatory disorders. Key areas include MAS biomarkers, DADA2 mechanisms, and immunometabolic drivers of inflammation. Scientific Contributions: Developed screening algorithms for lung disease in systemic JIA Characterized IL-17 elevation as Kawasaki disease biomarker Defined SOCS1 haploinsufficiency as autoimmunity driver Elucidated DADA2 vascular pathology mechanisms Dr. Lee actively contributes to clinical guidelines including international consensus statements on DADA2 management. His research bridges basic immunometabolism with translational applications for pediatric inflammatory disorders, with focus on identifying novel treatment targets for refractory conditions.

• Osteology
• Biomechanics
• Bone Remodeling
• +۵ مورد دیگر

Thorsten Schinke is a full-time faculty member and Professor at the Department of Osteology and Biomechanics , University of Hamburg-Eppendorf (UKE). His research focuses on molecular mechanisms of bone remodeling, Wnt/Notch signaling, osteoimmunology, and genetic factors in skeletal disorders. Key Research Themes: Wnt Signaling, Osteoporosis, Osteoimmunology, Skeletal Metastasis, Genetic Bone Diseases, Osteal Macrophages Scientific Contributions: Schinke has led 8 DFG-funded projects (2010-2021) exploring interactions between bone remodeling and disease states. His work includes identifying novel roles for Rsk2, PLS3, and Notch2 in osteosarcoma progression, X-linked osteoporosis, and Hajdu-Cheney syndrome. Using genetically engineered mouse models, he established connections between cytokine signaling (e.g., IL17, S1P), lysosomal dysfunction, and skeletal pathology. Recent Trends: Analysis of 15 recent publications (2017-2021) reveals expertise in in vivo bone modeling, histomorphometry, and cross-disciplinary approaches combining immunology and bone biology. Key subfields include tumor-bone interactions, Wnt-stimulated anabolism, and metabolic regulation of osteoblast/osteoclast balance. Scientific Awards: DFG Project 401122336 (2018-2021) DFG Project 385501541 (2017-2021) DFG Project 278045702 (2015-2019) DFG Project 235869912 (2013-2017) DFG Project 27463524 (2010-2014) Contact: Research conducted at Campus Lehre N55, Martinistrasse 52, Hamburg. Email: fis@uke.de

Maria Bohnertمشاهده پروفایل

استاد

• Cell Biology
• Molecular Biology
• Biochemistry
• +۳ مورد دیگر

Maria Bohnert serves as Professor at the Institute of Cell Dynamics and Imaging within the Medical Faculty of the University of Münster, where she leads the Bohnert Lab focused on organelle communication and cellular lipid homeostasis. Appointed as Gerty Cori Group leader since September 2018, she actively supervises students through the CiM-IMPRS Graduate Programme and contributes to the Cells in Motion interdisciplinary research cluster. Her academic foundation includes: 2002-2007: Diplom in Molecular Medicine (Dipl.Mol.Med.) from University of Freiburg 2007-2011: Doctor rerum naturalium (Dr.rer.nat) from University of Freiburg 2012-2015: Postdoctoral research at University of Freiburg 2015-2018: Postdoctoral research at Weizmann Institute of Science, Israel Bohnert's research program centers on lipid droplet (LD) dynamics and inter-organelle communication, employing robotic high-throughput microscopy screening to identify molecular players in LD contact sites. Her lab investigates how specialized molecular machines physically link organelles to exchange material and information, with particular focus on LD dysfunction in obesity, diabetes, lipodystrophy, and neurological disorders. This work bridges fundamental cell biology with translational implications for metabolic diseases. Analysis of her recent publications (2020-2025) reveals consistent investigation of organelle contact sites across multiple model systems, with predominant emphasis on lipid droplet interactions with peroxisomes, mitochondria, and vacuoles. Key thematic threads include identification of tethering proteins like Pex3 and seipin partners, metabolic regulation of contact site dynamics, and conserved mechanisms from yeast to mammalian systems. Her work demonstrates increasing methodological sophistication through cryo-EM and live-cell imaging approaches. As supervisor in the CiM-IMPRS Graduate Programme, Bohnert mentors next-generation scientists within the Cells in Motion research environment. Her lab maintains active collaborations with the Multiscale Imaging Centre and participates in the University Hospital Münster's research infrastructure, operating from the Institute of Cell Dynamics and Imaging facility at Von-Esmarch Str. 56.

Sheila Flemingمشاهده پروفایل

دانشیار

• Parkinson’s disease
• Behavioral neuroscience
• Neurodegenerative diseases
• +۳ مورد دیگر

Dr. Sheila Fleming is an Associate Professor of Pharmaceutical Sciences and Director of the Neurodegenerative Disease and Aging Research Focus Area at Northeast Ohio Medical University (NEOMED). She leads the Fleming Lab, which investigates molecular mechanisms underlying Parkinson’s disease (PD), focusing on alpha-synuclein aggregation, gene-environment interactions, and therapeutic interventions including exercise and immunotherapy. Her research employs behavioral neuroscience approaches combined with molecular and cellular analyses in rodent models. Current projects include studying the effects of treadmill exercise on cognitive and motor deficits in PD models, developing dance therapy protocols using motion capture technology, and exploring heavy metal exposure’s impact on neurodegeneration. Dr. Fleming’s work bridges basic science and translational research, with a focus on identifying therapeutic targets and improving patient outcomes. She has secured grants from NIH/NIEHS and the Department of Defense, including a study on ATP13A2’s role in neurodegeneration susceptibility and a project evaluating exercise’s efficacy in alpha-synuclein models of PD. The Fleming Lab collaborates widely, integrating genetics, pharmacology, and behavioral assessment to advance understanding of Parkinsonian pathology. Labs/Teams: Fleming Lab (NEOMED) focuses on Parkinson’s disease mechanisms and translational research. Grants: NIH/ NIEHS (1R01ES031124), DoD (W81XWH-19-0772). Key Contributions: Pioneered alpha-synuclein preformed fibril rat models, demonstrated exercise’s neuroprotective effects, and developed novel behavioral assays for PD phenotyping.

Jennifer Hirstمشاهده پروفایل

پژوهشگر

• Cell Biology
• Membrane Trafficking
• Hereditary Spastic Paraplegia
• +۶ مورد دیگر

Dr. Jennifer Hirst is a Principal Research Associate and Fellow at Jesus College, University of Cambridge, where she serves as a Tutor in Natural Sciences (Biological). She is based at the Cambridge Institute for Medical Research within the School of Clinical Medicine, focusing on cell biology and membrane trafficking research. Dr. Hirst earned her BSc Hons in Biochemistry from Imperial College London (as an Associate of the Royal College of Science), followed by a PhD in Cell Biology from University College London. She also completed a Diploma in Science Communication from Birkbeck College London, demonstrating her commitment to public engagement. Her research primarily investigates membrane trafficking mechanisms and their role in human diseases, particularly hereditary spastic paraplegia and lysosomal storage diseases. She has extensive expertise in endocytosis, cell culture, intracellular trafficking, live cell imaging, and molecular cell biology techniques. Her work examines how adaptor protein complexes (particularly AP-4 and AP-5) function in cellular trafficking pathways and how their dysfunction leads to neurodegenerative disorders. Analysis of her recent publications reveals a strong focus on hereditary spastic paraplegia, with particular emphasis on AP-4 and AP-5 complex deficiencies. Her research spans from basic molecular mechanisms to clinical applications, including development of diagnostic assays and potential gene therapies. She frequently collaborates on multicenter studies examining genetic mutations and their phenotypic expressions across different populations. Dr. Hirst is actively involved in public science engagement, conducting school science visits, and maintains personal interests in traveling, karate, and badminton. Her technical expertise includes advanced cellular imaging techniques, western blot analysis, and immunofluorescence, which support her investigations into protein trafficking pathways and neurological disease mechanisms.

Kostantin Dobrenisمشاهده پروفایل

دانشیار

• Neurodegenerative Diseases
• Lysosomal Storage Disorders
• Ganglioside Biology
• +۳ مورد دیگر

Kostantin Dobrenis is an Associate Professor in the Dominick P. Purpura Department of Neuroscience at Albert Einstein College of Medicine. His research focuses on neurodegenerative diseases and lysosomal storage disorders, including Tay-Sachs, Sandhoff, Niemann-Pick C, and mucolipidosis IV. He investigates therapeutic strategies to overcome blood-brain barrier challenges and enhance enzyme delivery, such as fusion proteins with tetanus toxin fragments. His lab also explores small molecule therapies like miglustat and cyclodextrin, and neuronal-microglial interactions for CNS therapy. Techniques include molecular biology, animal behavioral assays, and advanced imaging. Research interests emphasize ganglioside biology, microglial roles in neurodegeneration, and lysosomal enzyme transfer mechanisms. Key projects include cyclodextrin efficacy in Alzheimer’s models and NPC disease, as well as genetic mouse models to study disease pathogenesis. The lab collaborates on projects like CSF-1 receptor signaling in microglia and Slc9a6 knockout effects on brain development. His work bridges basic science and translational medicine, aiming to develop therapies for genetic CNS disorders. No awards listed, though his research has been published in high-impact journals like Neurobiology of Disease and Human Molecular Genetics . Advising and grants focus on training researchers in neurodegenerative disease mechanisms. The lab’s future directions include optimizing enzyme delivery systems and understanding microglia-neuron crosstalk in disease.

• Neuroinflammation
• Alzheimer's Disease
• Neurodegenerative Diseases
• +۶ مورد دیگر

Sue Griffin is a Professor at the University of Arkansas for Medical Sciences , affiliated with the College of Medicine and the Department of Geriatrics . She holds secondary appointments in Neurobiology & Developmental Science, Pediatrics, Physiology and Cell Biology, and Psychiatry. Her research focuses on neuroinflammation, Alzheimer’s disease, and the role of apolipoprotein E (APOE) genotypes in neurodegenerative pathogenesis. NIH/National Institute on Aging R01AG084472 (2023–2028): Principal Investigator on neuroinflammation, protein aggregates, and autophagy rescue NIH R01HD037989 (2000–2007): Principal Investigator on cytokines in neurodegeneration and Down's syndrome NIH P01AG012411 (1995–2021): Principal Investigator on early events in Alzheimer pathogenesis Her work spans interdisciplinary fields including neuroimmunology, protein homeostasis, and cytokine signaling. Publications highlight connections between inflammation (e.g., IL-1β), amyloid pathology, and genetic risk factors like APOE4. She has contributed to understanding neuroinflammatory mechanisms in Alzheimer’s, Parkinson’s, and Down’s syndrome. Griffin’s recent articles focus on therapeutic strategies targeting autophagy, neuroinflammatory signaling in glioblastoma, and microbial contributions to Alzheimer’s neuropathology. Her research has been supported by NIH grants for over three decades, with collaborations across neurology, genetics, and pharmacology. She is affiliated with the Institute on Aging and the Center for Translational Neuroscience . Her work has been cited in over 50 scientific concepts, including Alzheimer Disease, Epilepsy, and Apolipoproteins E.

Andrea De Vizcaya Ruizمشاهده پروفایل

استاد

• Environmental Toxicology
• Particulate Matter (PM2.5/PM10)
• Nanotoxicology
• +۴ مورد دیگر

Andrea De Vizcaya Ruiz is a Professor in the Department of Environmental and Occupational Health at the University of California, Irvine (UCI) School of Public Health . She is Graduate Program Director for Environmental Health Sciences and leads research at key centers including the Center for Occupational and Environmental Health (COEH) , Air Pollution Health Effects Lab (APHEL) , and AirUCI Atmospheric Integrated Research Unit . Her expertise spans environmental toxicology, nanotoxicology, and air pollution health impacts , with a focus on particulate matter (PM), microplastics, and nanomaterials. Educational Background: Bachelor's in Veterinary Medicine, National Autonomous University of Mexico (UNAM) Doctorate in Toxicology, University of Surrey, UK Research Interests center on toxic effects of environmental pollutants , including: Health impacts of particulate matter (PM2.5/PM10) Toxicokinetics of nanomaterials Oxidative stress and inflammation mechanisms Health equity in environmental exposure Neurotoxic and cardiorespiratory effects Biomarker development for toxicity assessment Recent Publications highlight her work on PM-induced nephrotoxicity, nanoparticle neurotoxicity, and synergies between urban pollutants and metabolic stressors . Her studies frequently employ in vitro and in vivo models to dissect toxicity pathways. Scientific Awards: 2011 Young Investigator Award, Society of Toxicology, USA 2015 1st place BioNanoTechnology Award, Cinvestav and Neolpharma Inc., Mexico City Student Mentorship includes advising PhD and MSc students like Aidee Solorio Rodriguez and Josefina Poblano Bata, with their work presented at international conferences including the International Nanotoxicology Congress and IUTOX Trainee Awards. Labs & Collaborations: She actively collaborates with research groups in Mexico, the Netherlands, Canada, and the US, integrating toxicology, aerosol science, and public health to address evolving biotechnology challenges. Her advisory roles for the Mexican Ministry of Health and Environment further demonstrate her policy impact.

• Medical Genetics
• Neurology
• Bioinformatics
• +۴ مورد دیگر

Professor Ahmet Okay Çağlayan at Dokuz Eylül University's School of Medicine specializes in Medical Genetics with a focus on neurodevelopmental disorders. His work integrates next-generation sequencing and genomic approaches to unravel rare genetic variants in structural brain abnormalities. Established Medical Genetics Department Teaching at undergraduate, graduate, and medical school levels Active in editorial and peer-review roles for top-tier journals Research spans neurogenetics, molecular diagnostics, and genomic medicine with emphasis on: Whole-exome sequencing applications Homozygosity mapping Linkage analysis Neurodevelopmental disease mechanisms Cortical malformations Genotype-phenotype correlations Recent publications highlight advancements in: Identifying novel pathogenic variants (NAGLU, KLHL40, PIBF1) Elucidating mTOR pathway dysregulation in lissencephaly Characterizing rare metabolic and neurodegenerative syndromes Developing genomic diagnostic frameworks for Turkish populations Metrics indicate: 197 WoS publications H-index: 4250 (Scopus) 24 research projects

• Ion Transport Physiology
• Molecular Cell Biology
• Biophysics
• +۳ مورد دیگر

Thomas J. Jentsch is a leading Professor at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, with secondary affiliation to the Max Delbrück Center (MDC) . He holds dual doctorates in Medicine and Physics from Freie Universität Berlin and has pioneered research in ion transport physiology since co-founding the Center for Molecular Neurobiology Hamburg in 1988. Head of Jentsch Group at FMP since 2006 World leader in chloride channel research His research bridges molecular physiology and human genetics , focusing on: CLC family chloride channels/transporters VRAC/LRRC8 volume-regulated channels ASOR/TMEM206 acid-activated channels Pathologies: neurodegeneration, deafness, osteopetrosis, hypertension Recent work includes breakthroughs in VRAC channel structure (2023) and CLCN7 channelopathies (2024). His lab employs genetically modified mouse models and human mutation analysis to uncover disease mechanisms.

• Ion Transport
• Neurobiology
• Cell Biology
• +۳ مورد دیگر

Thomas J. Jentsch is a Professor and Head of the Jentsch Group at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin. He holds dual doctoral degrees in Medicine and Physics from Freie Universität Berlin, with postdoctoral training in molecular cell biology at MIT/Whitehead Institute. His research focuses on ion transport mechanisms across cellular membranes, leveraging genetic mouse models and electrophysiological techniques. Key areas include CLC chloride channels/transporters, volume-regulated anion channels (VRAC/LRRC8), and acid-sensitive ASOR/TMEM206 channels. His work bridges molecular studies with systemic physiology, elucidating roles in neurodegeneration, epilepsy, deafness, osteopetrosis, and immune responses. Notable contributions include the discovery of VRAC (2014) and ASOR (2019), which revealed critical functions in tumor drug resistance, insulin secretion, and innate immunity. Current projects explore structure-function relationships of ion channels and their roles in organ-specific pathologies. Educational background: Medicine & Physics (Freie Universität Berlin), postdoctoral research at MIT/Whitehead Institute and ZMNH Hamburg. He transitioned to FMP/MDC Berlin in 2006, becoming a leader in chloride transport research. His lab employs interdisciplinary approaches combining genetics, biochemistry, and systems biology. Research interests span ion channel regulation, endosomal-lysosomal biology, and translational medicine. Recent work highlights VRAC’s role in cGAMP transport and immune signaling, as well as ASOR’s contributions to cellular pH homeostasis. Collaborations with groups like Xiao’s lab have advanced understanding of antiviral immunity pathways. Lab members include senior scientists Rosa Planells-Cases and Maya Polovitskaya, postdocs Sumanta Kar and Aleksandra Garifulina, and PhD students Tanushka Rana and Franziska Schmitt. Technical staff supports advanced imaging and molecular biology. Future directions emphasize structural biology of ion channels, clinical implications of VRAC/ASOR mutations, and leveraging mouse models for disease mechanisms. The lab actively seeks interdisciplinary postdocs to explore novel ion transport roles in health and disease.

Maysa Falahمشاهده پروفایل

مدرس

• Biomedical Sciences
• Pharmacology
• Epidemiology
• +۶ مورد دیگر

Maysa Falah is a Lecturer in Biomedical Sciences at the Peninsula Medical School, University of Plymouth. She holds a DPhil in Pharmacology from the University of Oxford and a specialization in Epidemiology/Public Health from Imperial College London. Her roles include leading Pathology education in the BMBS programme, coordinating Foundation Year Programmes across 15 healthcare disciplines, and supervising MSc dissertations in Global Health/Clinical Education. Her academic journey includes postdoctoral research on neurodegenerative disorders at Oxford’s Platt Lab (collaborating with Orphazyme) and industry-focused pharmacology teaching. Research interests span two core areas: (1) epidemiology of substandard/falsified medicines in LMICs and disaster zones, focusing on antibiotic quality and antimicrobial resistance; and (2) neuropharmacological interventions targeting lysosomal dysfunction and hippocampal sclerosis mechanisms. Recent publications explore pesticide toxicity profiles (encyclopedia entries on cypermethrin/deltamethrin/pyrethroids) and neuroprotective strategies using heat-shock protein pathways in NPC1 mouse models. Current projects investigate medication quality in post-earthquake Morocco (as PI for three active grants) and public awareness of poor-quality medicines in Jordan. Supervised students: Dr Rehab Osman (semaglutide efficacy), Dr Eman Mohammedi (essential oils in dermatology), Dr Kat Gangly (drug stability in extreme environments) Key initiatives: Adapted WHO medicine quality guidelines for disaster settings, pioneered team-based learning pedagogy in medical education Global Health Impact: Contributions to UN SDGs 3 (Good Health) and 17 (Partnerships)

Reuben Shawمشاهده پروفایل

استاد

• Cancer Biology
• Metabolic Disorders
• Cellular Metabolism
• +۳ مورد دیگر

Reuben Shaw, PhD, is a Professor and Director of the National Cancer Institute (NCI)-designated Cancer Center at the Salk Institute for Biological Studies. His research focuses on the interplay between cancer and metabolic diseases, particularly the role of the AMPK pathway in suppressing tumor growth and diabetes. Shaw discovered that the LKB1 tumor suppressor gene activates AMPK, linking cancer and diabetes metabolism. His lab develops therapies targeting metabolic vulnerabilities in cancers like lung cancer and metabolic disorders. Education: B.S. Biology, Cornell University Ph.D. Biology, Massachusetts Institute of Technology (MIT) Postdoctoral Fellow, Harvard Medical School Shaw’s research integrates cancer biology, metabolism, and drug development. Key areas include: Metabolic reprogramming in cancer cells Therapeutic potential of diabetes drugs (e.g., metformin) for cancer Mitochondrial repair mechanisms Lipid synthesis inhibition in non-small cell lung cancer Scientific Achievements: Discovered LKB1-AMPK connection, revolutionizing cancer-metabolism research Developed novel therapies targeting fat synthesis (e.g., ND-646) Uncovered mitochondrial stress responses and their role in diseases like Parkinson’s Grants & Collaborations: Shaw collaborates across disciplines at Salk, including metabolism, neuroscience, and plant biology. His work has led to NCI grants and partnerships with institutions like Harvard and MIT. Labs & Teams: Directs the Molecular and Cell Biology Laboratory, leading a team exploring metabolic vulnerabilities in cancer and metabolic diseases. Mentors next-generation researchers and fosters collaborative science.

• Physiology
• Neuroscience
• Synaptic Plasticity
• +۳ مورد دیگر

Karen Ting Chang, PhD , is an Associate Professor of Physiology and Neuroscience at the University of Southern California's Keck School of Medicine. Her research focuses on synaptic plasticity, mitochondrial dynamics, and molecular mechanisms in neurodegenerative diseases and developmental disorders. Using Drosophila models, she investigates how pathways like secretory autophagy, DSCR1 regulation, and integrin signaling affect neural function. Research Trends : Her publications highlight synaptic remodeling, calcium signaling, and cross-disease connections between Down syndrome and Alzheimer's pathology. Key methodologies include genetic models, endocytosis studies, and mitochondrial transport analysis. Contact : Email: changkt@usc.edu

• Cell Death
• Ferroptosis
• Redox Signaling
• +۵ مورد دیگر

Professor Marcus Conrad serves as Director of the Institute of Metabolism and Cell Death at Helmholtz Munich and holds the Chair of Translational Redox Biology at the Technical University of Munich (TUM) since 2024. His research bridges basic science and translation through the identification and pharmacological targeting of key nodes in cell death and necro-inflammatory processes. Conrad earned his PhD from Helmholtz Zentrum München and Ludwig-Maximilians-University Munich with highest honors (summa cum laude), focusing on selenoproteins in transgenic mice. His academic journey includes research positions at Karolinska Institute, Yamagata University, and leadership roles at Helmholtz Zentrum München before his current directorship. Conrad's research primarily focuses on ferroptosis, a regulated cell death pathway dependent on iron and lipid peroxidation. His work explores how understanding these molecular mechanisms can prevent neurodegenerative diseases and combat cancer. He has made significant contributions to understanding the role of GPX4, FSP1, and other key regulators in ferroptosis, with implications for drug discovery and therapeutic interventions. His publication record shows a strong focus on ferroptosis mechanisms, with recent work exploring novel ferroptosis suppressors, metabolic connections to cell death pathways, and implications for diseases including cancer, neurodegeneration, and kidney disease. His research demonstrates the growing recognition of ferroptosis as a critical pathway with therapeutic potential across multiple disease areas. Galenus-von-Pergamon-Price (2024) European Cell Death Organisation (ECDO) Honorary Award 2024 Multiple ISI Highly Cited Awards (2020-2024) ERC Advanced Grant "IRONDEATH" (2020) m4 Awards for Personalized Medicine (2012, 2017) Conrad has secured significant research funding including an ERC Advanced Grant and coordinates the Deutsche Forschungsgemeinschaft Priority Programme on Ferroptosis (2021-2026) involving 25 centers. He co-founded ROSCUE THERAPEUTICS GmbH in 2020, translating his research into potential therapeutics. Conrad actively mentors researchers through his institute and has organized multiple international conferences on ferroptosis, including EMBO workshops and Cold Spring Harbor Asia conferences. His institute at Helmholtz Munich serves as a hub for ferroptosis research, bringing together experts in redox biology, cell death mechanisms, and translational medicine. Conrad's leadership has positioned his team at the forefront of understanding how regulated cell death pathways can be targeted for therapeutic benefit in multiple disease contexts.